Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich Sells 2,627 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,627 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the sale, the chief operating officer now directly owns 26,961 shares in the company, valued at $1,300,059.42. This trade represents a 8.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Friday, January 24th, Peter Radovich sold 3,177 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $152,241.84.
• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $85,554.36.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $50.21 on Wednesday. The firm’s 50-day simple moving average is $44.39 and its 200 day simple moving average is $42.02. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $50.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm’s quarterly revenue was up 89.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.57) EPS. Research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Citigroup boosted their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Leerink Partners boosted their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and an average price target of $57.10.

Institutional Trading of Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Mirae Asset Global Investments Co. Ltd. raised its holdings in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the last quarter. R Squared Ltd bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $69,000. Avanza Fonder AB bought a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $189,000. Y Intercept Hong Kong Ltd bought a new stake in Mirum Pharmaceuticals during the 3rd quarter worth about $215,000. Finally, Creative Planning bought a new stake in Mirum Pharmaceuticals during the 3rd quarter worth about $249,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.